BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 29472724)

  • 41. Residual leukemic cell counts in the bone marrow at the end point of intensive induction therapy may be a prognostic factor for acute myeloblastic leukemia in adults.
    Fujisawa S; Maruta A; Motomura S; Fukawa H; Kanamori H; Ogawa K; Matsuzaki M; Miyashita H; Harano H; Murata T; Sakai R; Mohri H; Kodama F; Okubo T
    Leuk Lymphoma; 1998 Mar; 29(1-2):161-70. PubMed ID: 9638985
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
    Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
    Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.
    Ribeiro AF; Pratcorona M; Erpelinck-Verschueren C; Rockova V; Sanders M; Abbas S; Figueroa ME; Zeilemaker A; Melnick A; Löwenberg B; Valk PJ; Delwel R
    Blood; 2012 Jun; 119(24):5824-31. PubMed ID: 22490330
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next-generation sequencing technique.
    Wang RQ; Chen CJ; Jing Y; Qin JY; Li Y; Chen GF; Zhou W; Li YH; Wang J; Li DW; Zhao HM; Wang BH; Wang LL; Wang H; Wang MZ; Gao XN; Yu L
    Cancer Med; 2020 Nov; 9(22):8457-8467. PubMed ID: 32970934
    [TBL] [Abstract][Full Text] [Related]  

  • 45. DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant.
    Dillon LW; Gui G; Page KM; Ravindra N; Wong ZC; Andrew G; Mukherjee D; Zeger SL; El Chaer F; Spellman S; Howard A; Chen K; Auletta J; Devine SM; Jimenez Jimenez AM; De Lima MJG; Litzow MR; Kebriaei P; Saber W; Weisdorf DJ; Hourigan CS
    JAMA; 2023 Mar; 329(9):745-755. PubMed ID: 36881031
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation.
    Brambati C; Galbiati S; Xue E; Toffalori C; Crucitti L; Greco R; Sala E; Crippa A; Chiesa L; Soriani N; Mazzi B; Tresoldi C; Stanghellini MT; Peccatori J; Carrabba MG; Bernardi M; Ferrari M; Lampasona V; Ciceri F; Vago L
    Haematologica; 2016 Apr; 101(4):e157-61. PubMed ID: 26703962
    [No Abstract]   [Full Text] [Related]  

  • 47. Influence of DNMT3A R882 mutations on AML prognosis determined by the allele ratio in Chinese patients.
    Yuan XQ; Chen P; Du YX; Zhu KW; Zhang DY; Yan H; Liu H; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Yang J; Zeng WJ; Chen XP
    J Transl Med; 2019 Jul; 17(1):220. PubMed ID: 31291961
    [TBL] [Abstract][Full Text] [Related]  

  • 48. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
    Ahn JS; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):61-70. PubMed ID: 26234722
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genetic alteration patterns and clinical outcomes of elderly and secondary acute myeloid leukemia.
    Wang SY; Cheng WY; Mao YF; Zhu YM; Liu FJ; Ma TT; Shen Y
    Hematol Oncol; 2019 Oct; 37(4):456-463. PubMed ID: 31348835
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical relevance of
    Ferret Y; Boissel N; Helevaut N; Madic J; Nibourel O; Marceau-Renaut A; Bucci M; Geffroy S; Celli-Lebras K; Castaigne S; Thomas X; Terré C; Dombret H; Preudhomme C; Renneville A
    Haematologica; 2018 May; 103(5):822-829. PubMed ID: 29472349
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
    Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
    J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bioinformatics Analysis Identifies Key Genes and Pathways in Acute Myeloid Leukemia Associated with DNMT3A Mutation.
    Chen S; Chen Y; Lu J; Yuan D; He L; Tan H; Xu L
    Biomed Res Int; 2020; 2020():9321630. PubMed ID: 33299888
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Monosomal karyotype affecting outcomes of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission.
    Choi Y; Lee JH; Lee JH; Park HS; Choi EJ; Jo JC; Lee YJ; Lee YS; Kang YA; Lee KH
    Eur J Haematol; 2020 Sep; 105(3):262-273. PubMed ID: 32353911
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
    Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M
    J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448
    [TBL] [Abstract][Full Text] [Related]  

  • 55. DNMT3A mutations in Chinese childhood acute myeloid leukemia.
    Li W; Cui L; Gao C; Liu S; Zhao X; Zhang R; Zheng H; Wu M; Li Z
    Medicine (Baltimore); 2017 Aug; 96(31):e7620. PubMed ID: 28767575
    [TBL] [Abstract][Full Text] [Related]  

  • 56. AML evolution from preleukemia to leukemia and relapse.
    Shlush LI; Mitchell A
    Best Pract Res Clin Haematol; 2015; 28(2-3):81-9. PubMed ID: 26590763
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.
    Willekens C; Blanchet O; Renneville A; Cornillet-Lefebvre P; Pautas C; Guieze R; Ifrah N; Dombret H; Jourdan E; Preudhomme C; Boissel N;
    Haematologica; 2016 Mar; 101(3):328-35. PubMed ID: 26635039
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis.
    Wang R; Gao X; Yu L
    BMC Cancer; 2019 Apr; 19(1):389. PubMed ID: 31023266
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Persistence of DNMT3A mutations at long-term remission in adult patients with AML.
    Pløen GG; Nederby L; Guldberg P; Hansen M; Ebbesen LH; Jensen UB; Hokland P; Aggerholm A
    Br J Haematol; 2014 Nov; 167(4):478-86. PubMed ID: 25371149
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis.
    Limvorapitak W; Barnett MJ; Hogge DE; Forrest DL; Nevill TJ; Narayanan S; Power MM; Nantel SH; Broady R; Song KW; Toze CL; Mourad YA; Sutherland HJ; Gerrie AS; White J; Sanford DS
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e481-e491. PubMed ID: 30100330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.